Breaking News Instant updates and real-time market news.

TGT

Target

$110.86

0.27 (0.24%)

, LOW

Lowe's

$113.41

-1.62 (-1.41%)

20:25
11/19/19
11/19
20:25
11/19/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Target (TGT), consensus $1.19... Lowe's (LOW), consensus $1.35... NetEase (NTES), consensus $3.12... Copart (CPRT), consensus 59c... L Brands (LB), consensus 2c.

TGT

Target

$110.86

0.27 (0.24%)

LOW

Lowe's

$113.41

-1.62 (-1.41%)

NTES

NetEase

$288.77

-1.33 (-0.46%)

CPRT

Copart

$86.33

0.32 (0.37%)

LB

L Brands

$17.19

-0.67 (-3.75%)

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

TGT Target
$110.86

0.27 (0.24%)

11/11/19
KEYB
11/11/19
NO CHANGE
Target $130
KEYB
Overweight
Target price target raised to $130 from $120 at KeyBanc
KeyBanc analyst Edward Yruma raised his price target for Target to $130 from $120 and keeps an Overweight rating, telling investors in a research note that he believes Target is uniquely positioned to capture share from store closures in the mid-tier department. Share gains in the apparel and home furnishings categories should give Target continued margin expansion opportunity, Yruma adds.
11/07/19
NOMU
11/07/19
INITIATION
Target $123
NOMU
Buy
Target initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Michael Baker initiated coverage of Target with a Buy rating and $123 price target. The analyst sees the company as an "impressive turnaround candidate" operating in a favorable macro backdrop. Baker adds that Target's investment phase levers are gaining traction, which should drive sustained comp and market share gains.
11/07/19
CLVD
11/07/19
NO CHANGE
CLVD
Neutral
Target sales growth appeared to slow in back half of Q3, says Cleveland Research
Cleveland Research analyst said his work indicates that sales momentum appeared to slow a bit more than he was expecting at Target in the second half of the third quarter following a strong start. Based on his checks, he has lowered his Q3 comp store sales growth estimate to up 3.8% from 4.0%, though he note this is still above both consensus and guidance. The analyst, who also trimmed his Q3 EPS estimate by a penny to $1.24, keeps a Neutral rating on Target shares.
10/25/19
10/25/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Target (TGT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Kate McShane saying with the stock up 4% over the past month and 67% year-to-date, investor expectations already seem to be pricing in more of Target's progress. 2. Kinder Morgan (KMI) downgraded to Neutral from Buy at Goldman Sachs. 3. Avis Budget (CAR) downgraded to Hold from Buy at Deutsche Bank. 4. Vocera (VCRA) downgraded to Neutral from Outperform at Baird, to Neutral from Overweight at Cantor Fitzgerald, and to Hold from Buy at Craig-Hallum. 5. Pros Holdings (PRO) downgraded to Neutral from Overweight at JPMorgan with analyst Jackson Ader saying he has "mixed feelings" following last night's Q3 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LOW Lowe's
$113.41

-1.62 (-1.41%)

11/07/19
NOMU
11/07/19
INITIATION
Target $132
NOMU
Buy
Lowe's initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Michael Baker initiated coverage of Lowe's (LOW) with a Buy rating and $132 price target. The analyst calls the company a turnaround story helped by the favorable macro backdrop that should act as a tailwind. Baker believes Lowe's can generate significantly higher earnings as it closes the gap relative to Home Depot (HD).
11/15/19
JEFF
11/15/19
NO CHANGE
Target $268
JEFF
Buy
Home Depot price target raised to $268 from $246 at Jefferies
Jefferies analyst Jonathan Matuszewski raised his price target for Home Depot (HD) to $268 from $246 and keeps a Buy rating on the shares. The analyst also raised his price target for Buy-rated Lowe's (LOW) to $130 from $125. The analyst's channel checks point to Home Depot outperforming in brick and mortar as well as e-commerce in Q3. As a result, he lowered his Lowe's comp estimate below the consensus and raised his Home Depot comp estimate above the Street.
11/06/19
FBCO
11/06/19
UPGRADE
Target $129
FBCO
Outperform
Credit Suisse upgrades Lowe's to Outperform on 'compelling risk/reward'
Credit Suisse analyst Seth Sigman upgraded Lowe's (LOW) to Outperform from Neutral with a price target of $129, up from $114. The stock closed Tuesday down 42c to $112.20. The company's relative valuation versus closest peer Home Depot (HD) is near its trough level, industry demand is improving and there are "multiple sales/margin levers ahead," Sigman tells investors in a research note. As such, the analyst believes Lowe's offers a "compelling risk/reward" at current share levels. He expects Lowe's to report inline Q3 U.S. comps with acceleration into Q4 and 2020.
11/06/19
11/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Rollins (ROL) upgraded to Hold from Sell at Stifel with analyst Michael Hoffman saying the company has "reinvigorated" organic growth and when combined with more rapid consolidation of domestic Pest Control, it can likely drive double digit free cash flow growth for the next five years. 2. Tenet (THC) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he "solid trends" in the company's hospital business, including improving volumes, steady pricing growth, and "effective management" of underlying cost growth. 3. Blueprint Medicines (BPMC) upgraded to Strong Buy from Outperform at Raymond James with analyst Dane Leone citing the company's R&D update in NYC. 4. Lowe's (LOW) upgraded to Outperform from Neutral at Credit Suisse with analyst Seth Sigman saying the company's relative valuation versus closest peer Home Depot (HD) is near its trough level, industry demand is improving and there are "multiple sales/margin levers ahead." 5. Artisan Partners (APAM) upgraded to Buy from Neutral at Citi with analyst William Katz saying he sees potential for the company's net new assets to inflect positively into 2021, which he thinks should be enough to drive modest multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NTES NetEase
$288.77

-1.33 (-0.46%)

10/14/19
10/14/19
DOWNGRADE
Target $269.52

NetEase downgraded to Hold from Buy at UOB Kay Kian
UOB Kay Kian analyst Julia Pan downgraded NetEase to Hold from Buy with a price target of $269.52. The shares are now pricing in the positive news of a planned initial public offering of NetEase's education unit and disposal of its unprofitable e-commerce business Kaola, says the analyst.
08/12/19
08/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. NetEase (NTES) downgraded to Neutral from Buy at Goldman Sachs with analyst Bill Liu citing the company's Q2 revenues miss, mainly on soft online games growth. 2. Occidental Petroleum (OXY) downgraded to In Line from Outperform at Evercore ISI with analyst Doug Terreson saying the company's "pledge" for greater capital discipline and enhanced corporate governance "proved fleeting" with the significant decline in return on capital employed due to the Anadarko acquisition. 3. Adesto Technologies (IOTS) downgraded to Market Perform from Outperform at Northland with analyst Gus Richard saying the company has $34M of high interest debt and needs $10M to pay an earnout by year end, but he thinks the company is holding off on an offering until it reports a "strong" third quarter that will be boosted by an airpod win at Apple (AAPL). 4. Bluebird Bio (BLUE) downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying he's taking a conservative view on the company's transition from a development-stage company to a commercial-stage company. 5. Cemex (CX) downgraded to Market Perform from Outperform at BBVA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/19
SBSH
09/06/19
NO CHANGE
Target $326
SBSH
Buy
NetEase price target raised to $326 from $301 at Citi
Citi analyst Hillman Chan raised his price target for NetEase (NTES) to $326 from $301 saying he's positive on the sale of Kaola to Alibaba (BABA). The disposal signals NetEase's continuous focus on profitability and the additional funding to Cloud Music could make it more competitive versus Tencent Music (TME), Chan tells investors in a research note. The analyst expects investors to gradually assign value to NetEase's remaining non-gaming assets, like Cloud Music, and he keeps a Buy rating on the shares.
10/31/19
LEHM
10/31/19
NO CHANGE
Target $340
LEHM
Overweight
NetEase price target raised to $340 from $320 at Barclays
Barclays analyst Gregory Zhao raised his price target for NetEase to $340 from $320 and keeps an Overweight rating on the shares ahead of the company's Q3 results. The analyst views NetEase's disposal of its loss-making e-commerce division, Kaola, as a better allocation of its capital and resources. This should help NetEase avoid facing intense competition from China's online e-commerce market, while enhancing shareholder returns, Zhao tells investors in a pre-earnings research note.
CPRT Copart
$86.33

0.32 (0.37%)

10/18/19
GUGG
10/18/19
UPGRADE
Target $93
GUGG
Buy
Copart upgraded to Buy on Geico share gain at Guggenheim
As previously reported, Guggenheim analyst Ali Faghri upgraded Copart (CPRT) to Buy from Neutral with a $93 price target, citing the recent alignment of "two rare catalysts," namely an increase in buyer fees and a share win at "major customer" Geico. He sees these two factors driving mid-teens percentage, or higher, revenue growth over the next year for Copart, Faghri tells investors. For IAA (IAA), which lost the Geico share, the risk to 2020 consensus earnings is "manageable" given offsetting factors, added Faghri who believes the "bad news" is priced into the shares. He lowered his FY19 and FY20 estimates for IAA to reflect the Geico loss, which cut his price target on IAA to $46 from $50, though he keeps a Buy rating on the stock.
10/18/19
GUGG
10/18/19
UPGRADE
GUGG
Buy
Copart upgraded to Buy from Neutral at Guggenheim
08/14/19
RHCO
08/14/19
NO CHANGE
Target $53
RHCO
Buy
IAA price target raised to $53 from $47 at SunTrust
SunTrust analyst Stephanie Benjamin raised her price target on IAA (IAA) to $53 and kept her Buy rating after its Q2 earnings beat and maintained outlook for FY19 organic revenue growth. The analyst says the company is taking a "more aggressive approach" to online auctions, posting a 10% revenue growth, 6% volume growth, and 4% higher revenue per unit in the quarter. Benjamin also sees the implied premium 19-times her expected 2020 EBITDA multiple, which is above Copart's (CPRT) 14- to 17-times historic range, as justified based on IAA's greater ancillary service penetration with existing accounts and cost management.
07/08/19
BRRR
07/08/19
INITIATION
Target $43
BRRR
Market Perform
IAA initiated with a Market Perform at Barrington
Barrington analyst Gary Prestopino started IAA (IAA) with a Market Perform rating and $43 price target. The analyst believes IAA is fairly valued at a current 20% discount to Copart (CPRT). However, as the company successfully executes on its growth and margin improvement initiatives, this discount can narrow over time to 10% or less, Prestopino tells investors in a research note.
LB L Brands
$17.19

-0.67 (-3.75%)

11/11/19
DBAB
11/11/19
DOWNGRADE
Target $20
DBAB
Hold
L Brands downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Paul Trussell downgraded L Brands to Hold from Buy with a price target of $20, down from $31. The analyst's monthly promo watch indicates promotions remain at elevated levels. He believes most investors are cautious on Retailers heading into the Holiday, despite a generally healthy U.S. consumer, given a shorter window between Thanksgiving and Christmas as well as concerns around the promotional environment leading to bloated inventories. The analyst also lowered his price target for Sell-rated Macy's (M) to $32 from $36 and for Hold-rated Dillard's (DDS) to $22 from $23.
11/11/19
11/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying the stock is up 33% since August as Qualcomm's multiple has expanded relative to other semiconductor companies, which he attributes to the market assigning a high probability of a China-U.S. trade agreement, investors becoming more comfortable in a view that the FTC case won't materially impact the company's business, and expectations for the coming of 5G. 2. Lumentum (LITE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Meta Marshall saying operating margins have improved 300-400 basis points year-over-year since the Oclaro transaction closed and 3D sensing inventory correction issues that disrupted the trajectory last year did not repeat this year. 3. Cisco (CSCO) downgraded to Neutral from Overweight at Piper Jaffray with analyst James Fish citing a slowing macro environment across Enterprise and Service Provider, cycles hitting a peak earlier this year, a lack of a near-term catalyst, and risk to fiscal 2020 and 2021 estimates for the downgrade. 4. L Brands (LB) downgraded to Hold from Buy at Deutsche Bank with analyst Paul Trussell saying his monthly promo watch indicates promotions remain at elevated levels. 5. Expedia (EXPE) downgraded to Perform from Outperform at Oppenheimer with analyst Jed Kelly citing accelerating paid marketing, ADR pressures and Vrbo losing domestic share, all creating a tougher dynamic to sustain double-digit EBITDA growth than previously thought. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/19
LEHM
11/12/19
INITIATION
Target $16
LEHM
Underweight
L Brands initiated with an Underweight at Barclays
Barclays analyst Adrienne Yih initiated coverage of L Brands with an Underweight rating and $16 price target. The analyst cites the company's continued challenge in turning around the VS and PINK brands, its ongoing negative comps, and its inventory growth outpacing sales demand.
11/18/19
WEDB
11/18/19
NO CHANGE
Target $16
WEDB
Neutral
L Brands price target lowered to $16 from $20 at Wedbush
Wedbush analyst Jen Redding lowered her price target for L Brands to $16 from $20 ahead of the company's Q3 results on November 20, saying she sees downside to consensus estimates. Redding tells investors in a research note that her firm's data shows steep increases in markdown rates as likely driving sales, particularly at core Victoria's Secret, where margin weakness is more than offsetting strength in revenues at Bath & Body Works.

TODAY'S FREE FLY STORIES

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.